Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced the initiation of two Phase 2 Ultrafast Insulin treatment studies that utilize its rHuPH20 hyaluronidase enzyme (PH20) in combination with the two leading commercially available mealtime analogs: insulin aspart, the active ingredient in NovoLog®, and insulin lispro, the active ingredient in Humalog®. Diabetes patients enrolled in these cross-over design studies will receive an insulin analog alone and the Analog-PH20 treatment for 12 weeks each. Previous studies have demonstrated that the coinjection of rHuPH20 with an insulin analog results in a more physiologic fast-in, fast-out profile that enhances the mealtime glycemic control for each analog.
"These studies are designed to test whether the ultrafast profile of the Analog-PH20 insulin product will result in measurable benefits for patients with diabetes," stated Jonathan Lim, M.D., Halozyme's president and CEO. "We expect these studies will demonstrate that our rapid acting ultrafast insulin enables more patients to safely reach their A1C goal and to achieve better control of their blood glucose levels. Our partnership dialog is ongoing, and these studies will help support the clinical development and regulatory plans for a future partner."